NEW YORK (GenomeWeb News) — Vermillion has licensed a biomarker panel from Stanford University that could be used to assess the risk of peripheral artery disease, the company said today.
The agreement gives Vermillion exclusive rights to develop and commercialize a blood-based PAD test, which would use the multi-marker panel to stratify individual risk for developing the disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.